Clinical trials: Prostate Cancer Stage
Prostate Cancer
Biological Therapy in Treating Patients With Prostate Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells.
- Trial name
- NCT00002637
- Testing
- aldesleukin, gene-modified tumor cell vaccine therapy, recombinant interferon gamma
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Prostate Cancer
Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer
- Trial name
- MetAb-Pro (NCT01677897)
- Testing
- Metformin
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- Kantonsspital Graubünden
Prostate Cancer
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic…
- Trial name
- NCT03556904
- Testing
- Ablative Radiation Therapy, Hormone therapy or chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
This is a Phase I/Ib study of Radium-223 in combination with Tasquinimod for patients with bone metastases from castration-resistant prostate cancer (CRPC).
- Trial name
- Radium-223 (NCT02396368)
- Testing
- Tasquinimod, Radium 223
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received…
- Trial name
- NCT03834506
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 215 sites in United States, Argentina and 19 more
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of DWJ108J (leuprolide acetate) and Leuplin DPS Inj administered subcutaneously in patients with prostate cancer
- Trial name
- NCT03029533
- Testing
- Leuprolide Acetate
- Volunteers
- 44 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors.
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT05960578
- Testing
- Apalutamide, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Prostatic Neoplasms
Dose Escalation For INtraprostatic LEsions
External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer.
- Trial name
- DEFINE (NCT05851547)
- Testing
- Prostate SBRT with Focal Boost, Triptorelin Injection
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Ottawa Hospital Research Institute
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Prostate Cancer
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
Radiation and androgen deprivation is a common modality for patients with localized prostate cancer. Unfortunately for patients with intermediate to high risk prostate cancer incomplete tumor eradication and subsequent relapse…
- Trial name
- BrUOGPR255 (NCT01826838)
- Testing
- Dasatinib
- Sponsor
- Brown University
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more…
- Trial name
- NCT00067015
- Testing
- bicalutamide, goserelin acetate, assessment of therapy complications
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes
The purpose of this study is to examine the clinical feasibility and efficacy of uing IMRT to escalate the biologically effective dose to the pelvic lymph nodes in a short course of radiation therapy.
- Trial name
- NCT00214136
- Testing
- radiotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Prostatic Neoplasms
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk…
- Trial name
- PROTEUS (NCT03767244)
- Testing
- Apalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 2,517 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Prostatic Neoplasms.
- Trial name
- IRE (NCT02430649)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Diarrhea, Hormone-resistant Prostate Cancer
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel.
- Conditions
- Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT01469338
- Testing
- cabazitaxel, prednisone, octreotide pamoate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Southern California
Prostate Cancer
SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone
Abiraterone acetate (AA) has shown a favourable impact in overall survival, administered with prednisone to decrease the adverse event related to CYP171A suppression.
- Trial name
- NCT02928432
- Testing
- Steroids switch
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Prostate Cancer
Radium 223 Following Intermittent ADT
This is a multicentre, phase II, randomized, open label study to evaluate the efficacy and safety of monthly Radium 223 in prolonging the off treatment interval of men with localized prostate cancer receiving intermittent…
- Trial name
- RAND (NCT02656563)
- Testing
- Radium 223 Dichloride (Xofigo®)
- Where
- Canada
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer, Pain
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.
- Trial name
- NCT00503984
- Testing
- Azacitidine, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.